Other Income and Expense Items (Tables)

12 Months Ended

Jun. 30, 2026

Other Income and Expense Items [Abstract]

Schedule of Other income

(a) Other income

		30 June 2026 $				30 June 2025 $				30 June 2024 $
Interest			637,144				888,196				50,484
Research and Development tax incentive			10,097,238				9,368,544				1,292,578
			10,734,382				10,256,740				1,343,062

Schedule of Other Losses

(b) Other losses

		Notes		30 June 2026 $				30 June 2025 $				30 June 2024 $
Fair value adjustment on financing agreements					-				(489,787	)			366,719
Net foreign exchange (Losses)/Gains					(655,393	)			138,141				94,964
Loss on sale of available-for-sale assets		6(a)			(212,769	)			-				(1,687,791	)
					-				-				-
					(868,162	)			(351,646	)			(1,226,108	)

Schedule of Breakdown of Expenses by Nature

(c) Breakdown of expenses by nature

		Notes		30 June 2026 $				30 June 2025 $				30 June 2024 $
General and administrative expenses
Accounting and audit					949,683				957,895				845,818
Consulting					406,564				286,138				95,179
Depreciation					7,331				7,331				7,534
Employee benefits					11,186,055				10,120,149				9,448,779
Insurance					341,658				105,762				359,209
Investor relations					472,262				313,671				323,588
Legal					631,909				656,036				164,754
Listing and share registry					188,341				190,795				193,797
Patent costs					244,529				205,017				204,163
Travel and entertainment					864,801				808,546				427,676
Other					922,569				986,673				968,749
					16,215,702				14,638,013				13,039,246

Research and development
Amortization					2,698,702				2,588,306				3,118,752
AVb6 Integrin (TRIMT)					918,221				1,876,983				993,645
Consulting Fees R&D					1,324,355				930,292				929,229
hu PSA Anti-body (Diaprost)					7,011,056				2,925,445				298,312
Impairment		6(b)(viii)			5,266,823				-				1,478,892
R&D Ventures					11,040,742				5,989,964				3,931,541
NanoMab					15,070,282				7,185,000				6,501,174
Neoindicate					351,529				437,400				529,424
Pivalate - Imperial					6,153,044				5,184,136				3,962,355
UCLA					-				226,063				1,253,493
Other					128,145				171,605				89,450
					49,962,899				27,515,194				23,086,267